HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot

This article was originally published in The Pink Sheet

Executive Summary

The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.

You may also be interested in...



FDA New Drug Approval Count May Fall Back To Earth In 2016

A repeat of FDA’s record-breaking NME approval performance from recent years looks unlikely, even though the 14 novel approvals in the first half of 2016 equals the first half total for 2015, because almost one-third fewer novel candidates have user fee goals in the second half.

Perrigo Out From Under VMS Weight As IVC Lifts Private Label Profile

The cash deal for Perrigo's vitamins, minerals and supplements business will make International Vitamin Corporation the largest US private label nutritional product manufacturer and better position Perrigo to either continue on its own or as an even more attractive takeover target.

Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS123088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel